ORYZON awarded 13.26 million € through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)

Oryzon Genomics S.A., Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the publication of the Spanish provisional resolution proposal for Med4Cure, the first Important Project of Common European Interest (IPCEI) aimed to support research, innovation, and the first industrial deployment of pharmaceuticals and healthcare products in Europe, awarding Oryzon a non-refundable grant of 13,263,794 € (approximately 15 million USD) for its VANDAM project. This amount corresponds to 64% of the total accepted budget (20.68 million €) for the VANDAM Project.

Dr. Carlos Buesa, CEO of Oryzon, stated: “This grant is a key pillar of Oryzon’s clinical strategy, as it provides substantial financial resources that enable us to accelerate the next steps in the clinical development of vafidemstat for the treatment of CNS disorders. More importantly, it allows us to further explore vafidemstat’s therapeutic potential in managing aggression in rare diseases, such as subtypes of ASD, where an epigenetic approach has already been validated. We can now assess its effects not only across a broad range of ASD patients but also pursue a personalized medicine approach targeting genetically defined subpopulations, such as those with Phelan-McDermid syndrome, Fragile-X and others, thereby significantly strengthening our mental health program.”

Dr. Buesa continued, “In addition, this grant supports a more in-depth investigation of a personalized medicine strategy with our second compound, iadademstat, in rare tumors and genetically driven hematological diseases. These are areas of high unmet medical need and growing interest from the

pharmaceutical industry for innovative therapeutic options. We believe this program will drive meaningful progress and enhance the commercial potential of iadademstat. This multinational EU-backed initiative will play a critical role in ensuring access for European citizens—and future generations globally—to cutting-edge precision medicines for rare diseases.” Dr. Buesa added, “With our recent €30 million financing, this grant, and other additional inflows, the company now holds a solid cash position to execute our clinical development plans.”

Dr. Jordi Xaus, CSO of Oryzon added, “We wish to express our public gratitude to the EU officials and Spain’s Governmental agency CDTI for their support and valuable collaboration.”

VANDAM, acronym for “Validation of epigenetic Agents for Neuro-related rare Diseases Applying a personalized Medicine approach”, is a 44-month project aimed to develop effective therapies to address serious rare diseases, including rare neurodevelopmental disorders and rare neuroendocrine tumors caused by mutations and/or loss of function of genes mainly involved in chromatin regulation. The project aims to improve the quality of life of these patients, for whom there are no current treatment options, by deepening our understanding of the underlying molecular causes and developing targeted therapies that selectively address the etiopathogenesis of these diseases. The project started in January 2023 and will last until August 2026.

Med4Cure is a pan-European macro-project comprising 14 scientific initiatives developed by 13 companies as Direct Partners and 11 as Associated Partners, across six EU Member States: Belgium, France, Hungary, Italy, Slovakia, and Spain. In Spain, the project is coordinated by the Centro para el Desarrollo Tecnológico y la Innovación (CDTI) under the General Block Exemption Regulation (GBER) framework, in alignment with the requirements set by the Spanish CNU/1418/2024 call. Spain has integrated its participation in the IPCEI Med4Cure into the national Recovery and Resilience Plan, and funded by the Spanish Ministry of Science, Innovation and Universities and CDTI, with the potential for partial funding via the EU's Recovery and Resilience Facility. Oryzon is participating in Med4Cure as an Associated Partner within the consortium. Following the publication of the provisional resolution, the final resolution is expected within 3–4 weeks, with the grant to be disbursed in a single installment shortly thereafter.